We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Acer Therapeutics Inc. (ACER) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Acer Therapeutics Inc. (ACER - Free Report) closed at $2.18 in the latest trading session, marking a +1.87% move from the prior day. This move outpaced the S&P 500's daily loss of 0.16%. At the same time, the Dow lost 0.26%, and the tech-heavy Nasdaq gained 1.58%.
Heading into today, shares of the company had lost 9.7% over the past month, lagging the Medical sector's loss of 2.26% and the S&P 500's gain of 0.84% in that time.
Wall Street will be looking for positivity from Acer Therapeutics Inc. as it approaches its next earnings report date. In that report, analysts expect Acer Therapeutics Inc. to post earnings of -$0.39 per share. This would mark a year-over-year decline of 25.81%.
Investors should also note any recent changes to analyst estimates for Acer Therapeutics Inc.These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Acer Therapeutics Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 106, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ACER in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Acer Therapeutics Inc. (ACER) Gains As Market Dips: What You Should Know
Acer Therapeutics Inc. (ACER - Free Report) closed at $2.18 in the latest trading session, marking a +1.87% move from the prior day. This move outpaced the S&P 500's daily loss of 0.16%. At the same time, the Dow lost 0.26%, and the tech-heavy Nasdaq gained 1.58%.
Heading into today, shares of the company had lost 9.7% over the past month, lagging the Medical sector's loss of 2.26% and the S&P 500's gain of 0.84% in that time.
Wall Street will be looking for positivity from Acer Therapeutics Inc. as it approaches its next earnings report date. In that report, analysts expect Acer Therapeutics Inc. to post earnings of -$0.39 per share. This would mark a year-over-year decline of 25.81%.
Investors should also note any recent changes to analyst estimates for Acer Therapeutics Inc.These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Acer Therapeutics Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 106, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ACER in the coming trading sessions, be sure to utilize Zacks.com.